HFSA’s Annual Scientific Meeting is planned by and for cardiologists, nurses, pharmacists, and scientists, with something of interest to everyone on the heart failure team.
The 2017 program includes significant content in advanced heart failure, pharmacology, patient care, diagnosis and management, devices and technology, and bench-to-bedside translational science. It includes sessions for those new to heart failure and for established specialists.
HFpEF remains a challenging clinical syndrome to even define, let alone treat. This session will review how to define HFpEF for clinical practice and study design, how to integrate current diagnostic tools optimally, and how to apply existing and new technologies to advanced phenotyping of HFpEF.
Thus, there is an unmet need for new inotropic strategies. This session will review the clinical need for new inotropic strategies, the basic science underpinning novel strategies for enhancing cardiac contractility, and emerging date from proof-of-concept pre-clinical clinical research. Target audience is primarily physician and non-physician practitioners who care for patients with severe or unstable heart failure syndromes. Additionally, this session will be of value for clinical trainees and scientists involved with early and late therapeutic drug development.Speaker(s):